伊班膦酸钠联合化疗治疗转移性骨肿瘤

Clinical Effect of Skeletal Metastases Treated by Chemotherapy Combined with Ibandronate

目的:观察伊班膦酸钠联合化疗治疗转移性骨肿瘤的临床效果。方法:将138例转移性骨肿瘤患者随机分为:治疗组68例,即伊班膦酸钠联合化疗组;对照组70例,即单纯化疗组。两组病例同一病种化疗方案相同,治疗组患者在化疗结束后1周给予伊班膦酸钠4 mg+0.9%氯化钠注射液500 ml,ivd,时间>2 h,连用3周期后评价治疗效果。结果:治疗组控制局部疼痛有效率(CR+PR)77.9%,对照组30%,两组比较,P<0.05。溶骨性病灶的修复治疗组有效率61.8%,对照组21.4%,两组比较,P<0.05。治疗组功能改善有效率69.1%,对照组15.7%,两组比较,P<0.05。主要不良反应为类感冒样症状及一过性全身性骨痛。结论:伊班膦酸钠联合化疗治疗转移性骨肿瘤所致的疼痛效果好,用药不良反应轻,改善了患者的生活质量。

Objective： To observe the therapeutic effect of the treatment with intravenous （Ⅳ） ibandronate combined with chemotherapy on patients with skeletal metastases. Method： 138 patients with skeletal metastases were randomly divided into ibandronate group combined with chemotherapy （68 eases） and simple chemotherapy group （70 eases）. The controlled group took a standard chemotherapy project but combined the treatment group took a chemotherapy project plus ibandronate. In a week after the chemotherapy, 68 eases of the treatment group were treated with ibandronate 4mg in NS 500ml by intravenous infusion once 4 weeks for 3 months. The effect was evaluated when the three cycles finished. Result： There was a statistical difference （ P 〈 0.05 ） in local pain control in the treatment group, its total effective rate being 77.9%, and that of the controlled, 30% ; The repairing bone metastasis in the treatment group was 61.8% and that of the controlled, 21.4%. There as a statistical difference （ P 〈 0.05 ）. After the treatment, the activity of daily living （ADL） in the treatment group was 69.1% and that of the controlled, 15.7%. There was also a statistical difference （P 〈 0.05 ）. The major adverse effects included fever, headache, fatigue, nausea and skeletal pain. All of the adverse effects were mild. Condusion： Ibandronate combined with chemotherapy is effective for relieving pain in skeletal metastases, repairing bone metastasis and improving ADL The side-effects were mild to tolerate.